JND003 is a potent and selective ERRα agonist alleviating nonalcoholic fatty liver disease and insulin resistance. JND003 is orally bioavailable and exhibits high grade of distribution in liver and abdominal adipose tissues. Pharmacokinetics (PK) and Tissue Distribution Assays of JND003 were performed at Medicilon.

Reference

Liufeng Mao, et al. Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance. ACS Bio Med Chem Au. 2022 Jun 15;2(3):282-296. doi: 10.1021/acsbiomedchemau.1c00050.